AZEFLU®

Reg. San. No. INVIMA: INVIMA 2018M-0018440.
PRINCIPIO ACTIVO: Azelastina clorhidrato, Fluticasona propionato.
UNIDAD DE VENTA: Frasco PEAD con 30 mL, con bomba atomizadora nasal AP.

Mas Información

Referencias

  1. Bousquet J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*: ARIA: 2008 Update. Allergy 2008.
  2. Canonica GW, Mullol J, Pradalier A, Didier A. Patient Perceptions of Allergic Rhinitis and Quality of Life. World Allergy Organization Journal 2008.
  3. Dennis RJ, et al. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study. BMC Pulm Med 2012.
  4. Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. Journal of Allergy and Clinical Immunology [Internet] 2017.
  5. Hellings PW, et al. Explorative study on patient’s perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clinical and Translational Allergy 2012.
  6. Bousquet J, et al. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology 2016.
  7. Tan R, et al. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. asthma res and pract 2017.
  8. Wahid NWB, Shermetaro C. Rhinitis Medicamentosa. En: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
  9. Bousquet J, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology 2020.
  10. Meltzer EO, et al. Deposition characteristics of a novel intranasal formulation of azelastine hydrochloride plus fluticasone propionate in an anatomic model of the human nasal cavity. allergy asthma proc 2020.
  11. Klimek L, et al. MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review. Int Arch Allergy Immunol 2021.
  12. Carr W, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. Journal of Allergy and Clinical Immunology 2012.
  13. Price D, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol 2013.
  14. Williams DC, Edney G, Maiden B, Smith PK. Recognition of allergic conjunctivitis in patients with allergic rhinitis. World Allergy Organization Journal 2013.
  15. Seresirikachorn K, et al. Effects of H1 antihistamine addition to intranasal corticosteroid for allergic rhinitis: a systematic review and meta-analysis: Antihistamine and intranasal steroid. Int Forum Allergy Rhinol 2018.
  16. Hampel FC, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Annals of Allergy, Asthma & Immunology 2010.
  17. Bachert C, Bousquet J, Hellings P. Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management. Clin Transl Allergy 2018.
  18. Bousquet J, et al. Onset of Action of the Fixed Combination Intranasal Azelastine-Fluticasone Propionate in an Allergen Exposure Chamber. The Journal of Allergy and Clinical Immunology: In Practice 2018.
  19. Caballer B de la H, et al. Allergic Rhinitis and Its Impact on Work Productivity in Primary Care Practice and a Comparison with Other Common Diseases: The Cross-sectional Study to Evaluate Work Productivity in Allergic Rhinitis Compared with Other Common Diseases (CAPRI) Study. Am J Rhinol�Allergy 2012.
  20. Meltzer EO, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. allergy asthma proc 2012;33(4):324-32.
  21. Klimek L, et al. MP-AzeFlu provides rapid and effective allergic rhinitis control in real life: A pan-European study. allergy asthma proc 2016.
  22. Berger W, et al. MP ‐AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. Allergy 2016.
  23. Berger W, et al. Efficacy of MP ‐AzeFlu in children with seasonal allergic rhinitis: Importance of paediatric symptom assessment. Pediatr Allergy Immunol 2016.
  24. Berger W, et al. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: A randomized clinical trial. allergy asthma proc 2018.

 

Mas Información
Scroll al inicio